Terms: = Kidney tumors AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132
26 results:
1. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma.
Chang K; Chen Y; Zhang X; Zhang W; Xu N; Zeng B; Wang Y; Feng T; Dai B; Xu F; Ye D; Wang C
Cancer Res; 2023 Dec; 83(23):3940-3955. PubMed ID: 37713596
[TBL] [Abstract] [Full Text] [Related]
2.
Radic Savic Z; Coric V; Vidovic S; Vidovic V; Becarevic J; Milovac I; Reljic Z; Mirjanic-Azaric B; Skrbic R; Gajanin R; Matic M; Simic T
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629712
[TBL] [Abstract] [Full Text] [Related]
3. Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer.
Liu X; Liu L; Wang X; Jin Y; Wang S; Xie Q; Jin Y; Zhang M; Liu Y; Li J; Wang Z; Fu X; Jin CY
Phytomedicine; 2023 Sep; 118():154943. PubMed ID: 37421765
[TBL] [Abstract] [Full Text] [Related]
4. Association of nanoparticles and Nrf2 with various oxidative stress-mediated diseases.
Thiruvengadam R; Venkidasamy B; Samynathan R; Govindasamy R; Thiruvengadam M; Kim JH
Chem Biol Interact; 2023 Aug; 380():110535. PubMed ID: 37187268
[TBL] [Abstract] [Full Text] [Related]
5. FXR1 facilitates axitinib resistance in clear cell renal cell carcinoma via regulating keap1/Nrf2 signaling pathway.
Huang H; Zhang J; Jiang P; Xu X; Huang F; Zhao B; Wang X; Zhou L
Anticancer Drugs; 2023 Feb; 34(2):248-256. PubMed ID: 36730618
[TBL] [Abstract] [Full Text] [Related]
6. Catalytic activity tunable ceria nanoparticles prevent chemotherapy-induced acute kidney injury without interference with chemotherapeutics.
Weng Q; Sun H; Fang C; Xia F; Liao H; Lee J; Wang J; Xie A; Ren J; Guo X; Li F; Yang B; Ling D
Nat Commun; 2021 Mar; 12(1):1436. PubMed ID: 33664241
[TBL] [Abstract] [Full Text] [Related]
7. Ferroptosis in Liver Diseases: An Overview.
Capelletti MM; Manceau H; Puy H; Peoc'h K
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664576
[TBL] [Abstract] [Full Text] [Related]
8. BMP8A promotes survival and drug resistance via Nrf2/TRIM24 signaling pathway in clear cell renal cell carcinoma.
Yu YP; Cai LC; Wang XY; Cheng SY; Zhang DM; Jian WG; Wang TD; Yang JK; Yang KB; Zhang C
Cancer Sci; 2020 May; 111(5):1555-1566. PubMed ID: 32128917
[TBL] [Abstract] [Full Text] [Related]
9. Oxidative Stress and Cancer Development: Are Noncoding RNAs the Missing Links?
D'Souza LC; Mishra S; Chakraborty A; Shekher A; Sharma A; Gupta SC
Antioxid Redox Signal; 2020 Dec; 33(17):1209-1229. PubMed ID: 31891666
[No Abstract] [Full Text] [Related]
10. Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer.
Yamaguchi Y; Kamai T; Higashi S; Murakami S; Arai K; Shirataki H; Yoshida KI
BMC Cancer; 2019 Nov; 19(1):1137. PubMed ID: 31752777
[TBL] [Abstract] [Full Text] [Related]
11. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.
Ooi A
Semin Cancer Biol; 2020 Apr; 61():158-166. PubMed ID: 31689495
[TBL] [Abstract] [Full Text] [Related]
12. Downregulation of keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression.
Huang H; Wu Y; Fu W; Wang X; Zhou L; Xu X; Huang F; Wu Y
Int J Mol Med; 2019 May; 43(5):2044-2054. PubMed ID: 30896860
[TBL] [Abstract] [Full Text] [Related]
13. The impact of keap1/Nrf2, P
Hassanein EHM; Shalkami AS; Khalaf MM; Mohamed WR; Hemeida RAM
Biomed Pharmacother; 2019 Jan; 109():47-56. PubMed ID: 30396091
[TBL] [Abstract] [Full Text] [Related]
14. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel kidney Injury Biomarkers in Patients Receiving Cisplatin.
Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant C; Bowles DW; George B; Wen X; Aleksunes LM; Joy MS
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640195
[TBL] [Abstract] [Full Text] [Related]
15. keap1/Nrf2 pathway in kidney cancer: frequent methylation of keap1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract] [Full Text] [Related]
16. Cross-cancer profiling of molecular alterations within the human autophagy interaction network.
Lebovitz CB; Robertson AG; Goya R; Jones SJ; Morin RD; Marra MA; Gorski SM
Autophagy; 2015; 11(9):1668-87. PubMed ID: 26208877
[TBL] [Abstract] [Full Text] [Related]
17. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.
Kovac M; Navas C; Horswell S; Salm M; Bardella C; Rowan A; Stares M; Castro-Giner F; Fisher R; de Bruin EC; Kovacova M; Gorman M; Makino S; Williams J; Jaeger E; Jones A; Howarth K; Larkin J; Pickering L; Gore M; Nicol DL; Hazell S; Stamp G; O'Brien T; Challacombe B; Matthews N; Phillimore B; Begum S; Rabinowitz A; Varela I; Chandra A; Horsfield C; Polson A; Tran M; Bhatt R; Terracciano L; Eppenberger-Castori S; Protheroe A; Maher E; El Bahrawy M; Fleming S; Ratcliffe P; Heinimann K; Swanton C; Tomlinson I
Nat Commun; 2015 Mar; 6():6336. PubMed ID: 25790038
[TBL] [Abstract] [Full Text] [Related]
18. New strategies in renal cell carcinoma: targeting the genetic and metabolic basis of disease.
Srinivasan R; Ricketts CJ; Sourbier C; Linehan WM
Clin Cancer Res; 2015 Jan; 21(1):10-7. PubMed ID: 25564569
[TBL] [Abstract] [Full Text] [Related]
19. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
Wang YY; Yang YX; Zhe H; He ZX; Zhou SF
Drug Des Devel Ther; 2014; 8():2075-88. PubMed ID: 25364233
[TBL] [Abstract] [Full Text] [Related]
20. Integrated molecular analysis of clear-cell renal cell carcinoma.
Sato Y; Yoshizato T; Shiraishi Y; Maekawa S; Okuno Y; Kamura T; Shimamura T; Sato-Otsubo A; Nagae G; Suzuki H; Nagata Y; Yoshida K; Kon A; Suzuki Y; Chiba K; Tanaka H; Niida A; Fujimoto A; Tsunoda T; Morikawa T; Maeda D; Kume H; Sugano S; Fukayama M; Aburatani H; Sanada M; Miyano S; Homma Y; Ogawa S
Nat Genet; 2013 Aug; 45(8):860-7. PubMed ID: 23797736
[TBL] [Abstract] [Full Text] [Related]
[Next]
